Business
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita’s potential to be the first durable procedural therapy for post-GLP-1 weight maintenance
About this update from Fractyl Health, Inc.
[{"type":"image","alt":"Fractyl Health, Inc.","displaySize":"","headline":null,"caption":"Fractyl Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/grE4KlKD7t64vNihlXguCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5","width":300,"height":104}},"lazy":false},{"type":"text","content":"Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability","length":206,"tagName":"p"},{"type":"text","content":"Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months","length":135,"tagName":"p"},{"type":"text","content":"Results support pivotal study design and further substantiate Revita’s potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026","length":232,"tagName":"p"},{"type":"text","content":"Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying Revita under the De Novo pathway, which is expected in Q2 2026","length":183,"tagName":"p"},{"type":"text","content":"Company to host investor call and webcast today at 8:00 a.m. ET ","length":63,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company developing disease-modifying solutions for obesity and type 2 diabetes, today announced positive six-month randomized results from the ongoing REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita® for weight maintenance following GLP-1 drug discontinuation. These results reinforce the biological rationale for Revita, support the potential durability of effect, and provide increased confidence in the ongoing REMAIN-1 pivotal study.","length":611,"tagName":"p"},{"type":"text","content":"“These pilot study results build on our prior clinical experience and re...